Ajanta Pharma has launched Levetiracetam Immediate-Release Tablets (250mg, 500mg, 750mg, 1000mg) in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. Levetiracetam cures epileptic neurological disorder like numbness, blindness, paralysis or fits and is a bioequivalent generic version of Keppra.
The company’s launch of Levetiracetam Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the U.S. market. To date, the United States Food & Drug Administration (FDA) has granted Ajanta Pharma's eight ANDAs final approvals and two tentative approvals. An additional 16 ANDAs are pending approval from the FDA.
Ajanta Pharma is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 35 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: